9-14-2012

Resveratrol Effects on Astrocyte Function: Relevance to Neurodegenerative Diseases

Randall D. Wight
Ouachita Baptist University, wight@obu.edu

Cameron A. Tull
Ouachita Baptist University

Matthew W. Deel
Ouachita Baptist University

Brooke L. Stroope
Ouachita Baptist University

Amy G. Eubanks
Ouachita Baptist University

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.obu.edu/articles

Recommended Citation

This Article is brought to you for free and open access by the Faculty Publications at Scholarly Commons @ Ouachita. It has been accepted for inclusion in Articles by an authorized administrator of Scholarly Commons @ Ouachita. For more information, please contact mortensona@obu.edu.
Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases

Randall D. Wight¹, Cameron A. Tull¹, Matthew W. Deel¹, Brooke L. Stroope¹, Amy G. Eubanks¹, Janet A. Chavis², Paul D. Drew², and Lori L Hensley¹

¹Department of Biology, Ouachita Baptist University, Arkadelphia, AR 71998
²Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205

Abstract

Inflammatory molecules have been implicated in the pathogenesis of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. Resveratrol is an anti-fungal compound found in the skins of red grapes and other fruits and nuts. We examined the ability of resveratrol to inhibit lipopolysaccharide (LPS)-induced production of inflammatory molecules from primary mouse astrocytes. Resveratrol inhibited LPS-induced production of nitric oxide (NO); the cytokines tumor necrosis factor-alpha (TNF-α), interleukin 1-beta (IL-1β), and IL-6; and the chemokine monocyte chemotactic protein-1 (MCP-1), which play critical roles in innate immunity, by astrocytes. Resveratrol also suppressed astrocyte production of IL-12p40 and IL-23, which are known to alter the phenotype of T cells involved in adaptive immunity. Finally resveratrol inhibited astrocyte production of C-reactive protein (CRP), which plays a role in a variety of chronic inflammatory disorders. Collectively, these studies suggest that resveratrol may be an effective therapeutic agent in neurodegenerative diseases initiated or maintained by inflammatory processes.

Keywords

Resveratrol; Astrocyte; Nitric oxide; Cytokine; Chemokine; C-reactive protein

1. Introduction

The role of inflammatory processes in the pathogenesis of neurodegenerative diseases is well accepted but poorly understood [1]. Poorly controlled or chronic inflammatory activation of microglia and astrocytes has been implicated in the development and worsening of Alzheimer’s disease [2] Parkinson’s disease [3] multiple sclerosis [4], and other neurodegenerative disorders [5].

Astrocytes, resident central nervous system (CNS) glial cells with multiple metabolic and neurotransmission functions, have been implicated in the initiation and maintenance of
neurodegenerative processes and, alternatively, purported to protect against those processes-
[3,6,7]. Among the potential mechanisms for astrocytes contribution to disease development
and progression, the effects of astrocyte responses to pathogens and pro-inflammatory
cytokines appear likely. These responses include the production of nitric oxide (NO) and
multiple cytokines and chemokines under the control of transcription factor nuclear factor
κB (NF-κB). While these molecules are essential to normal immune function, chronically
high levels can interfere with normal function of the activated astrocyte and surrounding
cells of the CNS [5].

Resveratrol, a naturally occurring phytogenic estrogen [8] found in the skin of grapes, red
wine, mulberries, and several types of nuts, possesses anti-inflammatory properties [9]. Our
study examines resveratrol’s ability to suppress the production of inflammation-mediating
molecules in primary astrocytes extracted from mice. Specifically, in LPS-induced
astrocytes, we find dose-dependent effects of resveratrol on NO, TNF-α, IL-1β, IL-6,
MCP-1, IL-12p40, IL-23, and CRP. Given the role that chronically elevated levels of these
molecules may play in neurodegeneration, these findings suggest resveratrol may be an
effective agent for preventing or treating neurodegenerative diseases initiated or maintained
by inflammatory processes.

2. Materials and methods

Primary astrocyte cultures were obtained through a modification of the McCarthy and
deVellis protocol [10]. Briefly, cerebral cortices from 1–2 day-old C57BL/6 mice were
excised, meninges removed, and cortices minced into small pieces. Cells were separated by
trypsinization followed by trituration of cortical tissue. Cells were plated into tissue culture
flasks and allowed to grow to confluence (approximately 10 days) in DMEM media
containing 10% FBS, 1.4mM glutamine, and OPI media supplement (Sigma, St. Louis,
MO). Flasks were shaken overnight (200 rpm at 37°C) in a temperature controlled shaker to
loosen microglia and oligodendrocytes from the more adherent astrocytes. L-LME (0.1 mM)
was added to the cultures to eliminate any residual microglia. Using this procedure,
astrocyte cultures of greater than 95% purity were obtained as determined by
immunohistochemistry with antibodies prepared against GFAP for astrocytes and the lectin,
Griffonia simplicifolia (GSA) to measure contaminating microglia. Astrocytes were seeded
into 96-well plates. The following day, cultures were treated for 1 h with the indicated
concentrations of resveratrol followed by treatment for 24 h with 2μg/ml lipopolysaccharide
(LPS). Tissue culture supernatants and cells were collected for cell viability, nitrite, and
ELISA assays, which were conducted as we have described previously [11].

3. Results

Resveratrol inhibited NO production in a dose-dependent manner (Figure 1A). Resveratrol
was not toxic to astrocytes in these studies as determined by MTT assays, indicating that
resveratrol suppression of NO by primary astrocytes was not due to astrocyte cell death
(Figure 1B).

LPS induced the production of inflammatory cytokines TNF-α (Figure 2A), IL-1β (Figure
2B), IL-6 (Figure 2C), and MCP-1 (Figure 2D) which are molecules that play critical roles
in innate immunity. In addition, resveratrol inhibited LPS induction of IL-12 (Figure 3A)
and IL-23 (Figure 3B), which are cytokines that are capable of altering the phenotype of T
cells that are critical to adaptive immunity. Finally, resveratrol suppressed LPS-induction of
CRP (Figure 4) by primary astrocytes, and CRP has been associated with a variety of
chronic inflammatory disorders. Resveratrol suppressed astrocyte production of these
inflammatory molecules in a dose-dependent manner. Collectively, these studies indicate
that resveratrol is effective in the suppression of a variety of pro-inflammatory molecules,
and thus may be effective in the treatment of neuroinflammatory and neurodegenerative disorders.

4. Discussion

Resveratrol has been shown to be neuroprotective against ischemia-induced injury [12], β-amyloid-induced neurotoxicity [13], autoimmune-mediated injury [14], and various other inflammation-mediated contributors to neuronal cell death and dysfunction [15]. Recent studies have examined the effects of resveratrol on specific pro-inflammatory molecules in the CNS, including NO [16] and cytokines under the influence of NF-κB [17]. However, most studies of relevance to neurodegenerative diseases have focused on resveratrol’s effects in microglia and not astrocytes.

As reviewed by Quincozes-Santos & Gottfried [18], many of the neuroprotective effects of resveratrol may be mediated by the compound’s modulatory actions on astrocytes. Potentially protective actions in astrocytes include modulation of glutamate homeostasis, modulation of ischemia-induced mitochondrial dysfunction, and suppression of acute and chronic inflammation.

A recent study indicated that resveratrol’s effects on mediators of inflammation may not be identical in microglia and astrocytes. Lu and colleagues [19] found that resveratrol was a more potent suppressor of TNF-α, IL-6, MCP-1, and NO production in mouse microglia than in mouse astrocytes. They also found that resveratrol suppressed IL-1β production in microglia but not in astrocytes. In contrast, we found that resveratrol significantly suppressed IL-1β production at concentrations that did not affect the viability of astrocytes. Interestingly, we also demonstrate for the first time that resveratrol inhibits LPS induction of IL-12p40 and IL-23 by primary astrocytes. These cytokines play a critical role in the differentiation of Th1 and Th17 cells known to contribute to the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis [20]. Resveratrol suppresses the development of EAE [14] Our studies suggest that resveratrol may suppress EAE, at least in part, through suppressing the development of Th1 and Th17 cells.

The potential link between elevated serum levels of CRP and cardiopathology has received significant attention. More recent studies suggest a potential link between high serum levels of CRP with the presence and severity of AD [21] and PD [22,23,24], suggesting a role of CRP in the pathogenesis of neurodegenerative diseases. A recent study indicates that pro-inflammatory cytokines induce CRP expression in primary microglia [25]. To the best of our knowledge, the current study is the first demonstration of CRP expression by astrocytes and the first to demonstrate that resveratrol inhibits LPS-induction of CRP production in these cells. These studies suggest that resveratrol may suppress the development of neurodegenerative diseases in part by suppressing CRP expression by astrocytes.

In summary, we demonstrated that resveratrol inhibits astrocyte production of several molecules implicated in innate immunity and neurodegeneration. Furthermore, we demonstrate for the first time that resveratrol suppresses the production of IL-12 and IL-23. This suggests that resveratrol could suppress EAE by suppressing the development of Th1 and Th2 cells. Finally, we present the first evidence that resveratrol suppresses astrocyte production of CRP. Collectively, these studies suggest that resveratrol may prove valuable in the treatment of CNS diseases characterized by neuroinflammation and neurodegeneration.
Acknowledgments

The authors thank Barry Gehm and Timothy Hayes for helpful discussions, and Sean Daly for technical assistance. This work was supported by NIH grants NCRR 5P20RR016460-11, NIGMS 8P20GM103429-11 and NS047546.

References


- Resveratrol inhibited astrocyte production of cytokines and chemokines.
- Resveratrol inhibited production of C-reactive protein by astrocytes.
- Resveratrol may be effective in the treatment of neurodegenerative diseases.
Figure 1. Resveratrol suppresses production of nitrite in LPS-stimulated primary astrocytes
Cells were pre-treated for 1h with the indicated concentrations of resveratrol (μg/ml). LPS (2μg/ml) was added and cells were incubated for 24h. The concentration of nitrite was measured using Greiss reaction (A). Cell viability was determined by MTT assay (B), and resveratrol had no effect on cell viability. Values represent the mean +/- s.e.m. for triplicate cultures. *** indicates p<.001 vs. LPS treated cultures. Data were analyzed by ANOVA followed by a Bonferroni test to determine the significance of difference. These data are representative of three independent experiments.
Figure 2. Resveratrol suppresses production of inflammatory mediators by primary astrocytes

Cells were pre-treated with resveratrol at the indicated concentration (μg/ml) for 1h, LPS (2μg/ml) was added, and cells were incubated for 24h. Concentrations of inflammatory mediators (TNF-α, A; IL-1β, B; IL-6, C; and MCP-1, D) in the culture medium were determined by ELISA. Values represent the mean +/- s.e.m. for triplicate cultures. * indicates p<.05, ** indicates <.01, and *** indicates <.001 vs. LPS treated cultures. Data were analyzed by ANOVA followed by a Bonferroni test to determine the significance of difference. These data are representative of three independent experiments.
Figure 3. Resveratrol suppresses production of IL-12 family cytokines by primary astrocytes

Cells were pre-treated with resveratrol at the indicated concentration (μg/ml) for 1h, LPS (2μg/ml) was added, and cells were incubated for 24h. Concentrations of inflammatory mediators (IL-12p40, A; and IL-23, B) in the culture medium were determined by ELISA. Values represent the mean +/- s.e.m. for triplicate cultures. ***indicates p<.001 vs. LPS treated cultures. Data were analyzed by ANOVA followed by a Bonferroni test to determine the significance of difference. These data are representative of three independent experiments.
Figure 4. Resveratrol suppresses production of C-reactive protein by primary astrocytes
Cells were pre-treated with resveratrol at the indicated concentration (μg/ml) for 1h. LPS (2μg/ml) was added, and cells were incubated for 24h. Concentrations of CRP in the culture medium were determined by ELISA. Values represent the mean +/- s.e.m. for triplicate cultures. **indicates p<.01, and ***indicates p<.001 vs. LPS treated cultures. Data were analyzed by ANOVA followed by a Bonferroni test to determine the significance of difference. These data are representative of three independent experiments.